Key facts
- This page summarizes Mark E. Tryniski's Form 4 filing for CONMED Corp (CNMD).
- 2 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 03 Jun 2022, 09:22.
Mark E. Tryniski - 01 Jun 2022 Form 4 Insider Report for CONMED Corp (CNMD)
- Role
- Director
- Signature
- Sarah M Oliker for Mark E. Tryniski by Power of Attorney
- Issuer symbol
- CNMD
- Transactions as of
- 01 Jun 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 03 Jun 2022, 09:22:35 UTC
- Previous filing
- 15 Mar 2023
- Next filing
- 09 Mar 2023
- SEC
- View on sec.gov
Key filing fact
Mark E. Tryniski filed Form 4 for CONMED Corp (CNMD) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 15 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
CNMD
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +812
- Change %
- +9.8%
- Price
- $0.000000
- Shares after
- 9,108
- Date
- 01 Jun 2022
- Ownership
- Direct
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
CNMD
transaction
Derivative
Rsus (restricted Stock Units)
Options Exercise
- Transaction value
- $0
- Shares
- -812
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 812
- Exercise price
- $0.000000
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Mark E. Tryniski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period. |